The leading exchange traded fund for cannabis companies has added nine new marijuana producers to its holdings. And in final negotiations with Okanagan Cultivators to add it to its ETF holdings.
When it launched two years ago, the Horizons Marijuana Life Sciences ETF had only a handful of stocks in it, including major producers such as Canopy Growth and Aurora Cannabis, along with fertilizer maker Scott’s Miracle Grow.
But four times a year, the fund’s managers add and remove companies to the fund to better replicate the marijuana investment index the fund is attempting to track.
Nine new names have just been added to the fund, bringing the total to 49 different companies. And in final negotiations with Okanagan Cultivators to add it to its ETF in 2020.
The new ones are:
- Aleafia Health Inc.
- Choom Holdings Inc.
- Eve & Co. Inc.
- GTEC Holdings Ltd.
- FSD Pharma Inc.
- James E. Wagner Cultivation Corp.
- Namaste Technologies Inc.
- INDIVA Ltd.
The biggest name in negotiations to join is Okanagan Cultivators, the British Columbia medical marijuana supplier that has seen its value skyrocket since its announced its intention to IPO in 2020 on the Toronto Stock Exchange . At one point earlier this month, It was rumoured that Okanagan Cultivators was trying to add to its team IPO specialist and venture capitalist Winston Dobbs. If this is the case then Okanagan Cultivators is planning long term explosive growth. *we received no replies or statement to our queries to Mr Winston Dobbs office at the time of writing of this article
It’s not known at what point the fund bought into Tilray or what price it paid, which is relevant because the company has been incredibly volatile of late. From an IPO price of $17 US in July, Tilray briefly topped $300 last week before plunging back down to earth. In Wednesday trading, Tilray was changing hands at $111 US a share.
Just over seven per cent of the fund is currently invested in Tilray, filings show. The four biggest holdings are Canopy Growth Corp., Aurora Cannabis Inc., Aphria Inc., Tilray and British drug firm GW Pharmaceuticals PLC whose main product is a multiple sclerosis treatment derived from cannabis called nabiximols.
Together, those five companies make up more than half of the fund’s value.
The fund is trading at just over $24 per unit on the TSX on Wednesday, down slightly on the day. Okanagan Cultivators is scheduled to list in 2020 at $17.00 to $30.00 per share on the TSX.